Background and Aim: A high yield of biopsy is mandatory to perform molecular genetic research with endoscopically obtained gastric cancer tissues. We evaluated whether probebased confocal laser endomicroscopy (pCLE) can increase the yield of endoscopic biopsy for gastric cancer compared with white light endoscopy (WLE). Methods: All lesions in the pCLE and WLE groups were initially evaluated through WLE. In the pCLE group, lesions were further examined through pCLE. In the pilot study, five and three biopsy specimens were obtained for histopathological examination and tumor marker analysis, respectively. In the confirmatory study, six biopsy specimens for histopathological evaluation were obtained. Results: A total of 30 gastric cancers and 61 undifferentiated-type gastric cancers were analyzed in the pilot and confirmatory studies, respectively. The proportion of cancer cells in biopsy samples of poorly differentiated adenocarcinoma or signet ring cell carcinoma was higher in the pCLE group than in the WLE group in both the pilot and confirmatory studies (pilot: median proportion, 65% vs 30%, P = 0.010; confirmatory: mean ± standard deviation, 49.5 ± 29.3 vs 29.3 ± 13.7, P = 0.002). The expression ratio of tumor markers including carcinoembryonic antigen, GW112, HOX transcript antisense RNA, and H19 tended to be higher in the pCLE group than in the WLE group. Conclusion: Probe-based confocal laser endomicroscopy-targeted biopsy provided superior results in terms of the proportion of cancer cells in biopsy samples compared with WLE-targeted biopsy in gastric cancer with undifferentiated histology.
Introduction
Nowadays, molecular genetic pathology is in the spotlight in the evaluation of gastric carcinogenesis. Many investigators have attempted to classify heterogeneous populations of patients with gastric cancer into biologically homogeneous subgroups. [1] [2] [3] Additionally, noncoding genomic components including micro-RNAs and long noncoding RNAs have been the focus of investigations as potential biomarkers for the diagnosis or prognosis of gastric cancer. 4, 5 Such efforts may lay a foundation for the development of personalized medicine.
However, there are some problems with a molecular approach to gastric cancer. Although a definitive diagnosis of gastric cancer is made by means of histopathological examination, this examination is often unavailable when fresh gastric cancer tissues are obtained. In vivo diagnostic techniques including conventional white light endoscopy (WLE) can be a second-best option for the diagnosis of gastric cancer; however, the diagnostic yield of a single endoscopic biopsy is not optimal. 6 The low yield of endoscopic biopsy degrades the reliability of tissue biomarker values measured from endoscopically obtained samples. If molecular genetic research is planned for gastric cancer with endoscopic biopsy samples, the suboptimal diagnostic performance of gross endoscopic findings with biopsy under WLE may reduce the accuracy of the study results. Although various endoscopic techniques including chromoendoscopy, magnifying endoscopy, and narrow band imaging have been developed, their diagnostic performance is still limited especially in gastric cancers with undifferentiated histology. [7] [8] [9] Therefore, researchers should upgrade the performance of endoscopic diagnosis at the stage of biopsy before histopathological examination.
In this situation, confocal laser endomicroscopy (CLE) can be a solution for increasing the yield of endoscopic biopsy. CLE is a new imaging technique that provides real-time, in vivo, highresolution, and high-magnification images. 10, 11 Many studies have demonstrated that CLE offers high accuracy for the diagnosis of gastric cancer, adenoma, and intestinal metaplasia. [10] [11] [12] [13] [14] Additionally, the technique can decrease the number of required endoscopic biopsies. 10 Therefore, we speculated that the proportion of cancer cells in biopsy samples might be increased with CLE examination especially in gastric cancers with undifferentiated histology. We aimed to evaluate whether probe-based CLE (pCLE) can increase the yield of endoscopic biopsy for undifferentiated gastric cancer compared with WLE.
Methods
Study population. Adult patients between the ages of 20 and 80 years who were diagnosed as having gastric cancer were recruited for this study. Written informed consent was obtained from all patients. Patients who had previously undergone subtotal gastrectomy were excluded. The study protocol was approved by the Institutional Review Board and Hospital Research Ethics Committee of Severance Hospital and registered at http://www. clinicaltrials.gov (clinical trial registration number: pilot study, NCT02089373, March 17, 2014; confirmatory study, NCT02799420, June 14, 2016).
Pilot study. As a pilot study, we recruited 30 patients with gastric cancer. The patients were randomly assigned in a 1:1 ratio, by using a table of computer-generated random numbers with sealed envelopes, to either the WLE group or the pCLE group. The allocation system was created by one of the study investigators (C. H. P.).
All endoscopic examinations and biopsies were performed by one experienced endoscopist (S. K. L.). The endoscopist inevitably became aware of the group allocation of patients. In the pCLE group, lesions were examined with both WLE and pCLE. After the careful observation of lesions under WLE, sodium fluorescein (2.5 mL, 10%) was injected intravenously. Then, a confocal miniprobe (field of view 240 μm, lateral resolution 1 μm; GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France) was passed through the endoscope accessory channel and placed in gentle contact with the lesion. The Miami classification for pCLE interpretation was used to differentiate gastric cancer from normal tissue 11 ; however, there is no current widely accepted CLE classification for gastric lesions. After overall inspection of the whole lesion with pCLE, the area that showed the most distinct features of gastric cancer was selected as the target biopsy site. The pCLE probe was then removed, and the biopsy forceps was introduced to obtain five samples for histopathological evaluation and three samples for tumor marker analysis. In the WLE group, five biopsy specimens for histopathological evaluation and three biopsy samples for tumor marker analysis were obtained from suspicious lesions. If there is ulceration in the lesion, biopsy was performed on the inner margin of the ulcer in all directions. Three additional biopsy samples for tumor marker analysis were obtained from adjacent normal tissues in both groups.
Confirmatory study. After analyzing the data from the pilot study, we planned a confirmatory study. Because we had identified the superior yield of pCLE in gastric cancer with undifferentiated histology through the pilot study, patients with biopsy-proven poorly differentiated adenocarcinoma (APD) or signet ring cell carcinoma (SRC) were recruited for the confirmatory study. Sequence generation and allocation concealment were conducted in the same manner as in the pilot study. The procedural techniques of WLE and pCLE were also performed in the same manner as in the pilot study; however, only six biopsy specimens were obtained from lesions for histopathological evaluation in the confirmatory study. Patients who were finally diagnosed as having gastric cancer with differentiated histology after surgery or endoscopic submucosal dissection were excluded from the analysis.
Histopathological assessment. All de-identified slides were sent to the pathology department and read by a single blinded expert gastrointestinal pathologist (H. K. in the pilot study and J. H. J. in the confirmatory study). The final pathological diagnoses were classified as gastric cancer with differentiated or undifferentiated histology according to the Japanese classification. 15 The undifferentiated type included APD, SRC, and mucinous adenocarcinoma, whereas the differentiated type included papillary adenocarcinoma and well differentiated to moderately differentiated adenocarcinoma. The proportion of cancer cells in biopsy samples was visually evaluated by the pathologist.
Tissue tumor marker assessment. From a review of the literature, genes and noncoding RNA that represent gastric cancer were selected, including carcinoembryonic antigen (CEA), GW112, HOX transcript antisense RNA (HOTAIR), and H19. 4, [16] [17] [18] The total RNA was extracted from gastric cancer tissues and adjacent normal tissues by using TRIzol reagent (Invitrogen, Camarillo, CA, USA); cDNA was synthesized from 2.0 μg total RNA according to the manufacturer's instructions. The levels of tumor markers including CEA, GW112, HOTAIR, and H19 were measured by performing quantitative real-time polymerase chain reaction (qRT-PCR) with iQ SYBR Green Supermix (Applied Biosystems Inc., Carlsbad, CA, USA). The expression of tissue tumor markers was calculated with the 2 -ΔΔCT method by using glyceraldehyde-3-phosphate dehydrogenase. The tumor marker expression was compared between cancer tissues and adjacent normal tissues. Then, the expression ratio (cancer to normal) was compared between the WLE and pCLE groups. The primers used for qRT-PCR are listed as follows:
Study endpoints. The primary endpoint of this study was the comparison of the proportion of cancer cells in biopsy samples of APD or SRC between the WLE and pCLE groups. Additionally, the number of biopsy samples that contained cancer cells and the expression of tissue tumor markers were assessed as secondary endpoints.
Sample size calculation. In the pilot study, the sample size of each group was determined as 15 (total study size 30), because relevant data for sample size calculation were unavailable. Additionally, the sample size of the confirmatory study was determined according to the results of the pilot study. The proportion of cancer cells was assumed to be 65% and 30% in the pCLE and the WLE, respectively. To achieve 80% power to detect a difference between the group proportions of 35%, with a significance level of 5%, 62 patients would be needed. As a result, we planned to recruit 74 patients with biopsy-proven APD or SRC considering a 15% dropout rate. 
Results
Study population. The flow diagram of this study is shown in Figure 1 . In the pilot study, 30 patients who were assessed for eligibility between April 2014 and March 2015 were randomly assigned to either the WLE group (n = 15) or the pCLE group (n = 15). After randomization, all patients received their allocated intervention, and none were lost to follow up or excluded from the analysis. In the confirmatory study, 74 patients with biopsy-proven APD or SRC were assessed for eligibility between May 2016 and May 2017. One patient declined to participate the study. The remaining 73 patients were randomly allocated to either the WLE group (n = 38) or the pCLE group (n = 35). Of 73 enrolled patients, 10 were dropped out in the study because they were finally diagnosed as having neither APD nor SRC through surgery or endoscopic submucosal dissection. In the pCLE group, additionally, two patients with small early gastric cancer were excluded in the analysis because cancer cells were not detected in the pCLE. In these two patients, tissue sampling was performed by means of random biopsy instead of pCLE-targeted biopsy.
Baseline characteristics. The baseline patient and lesion characteristics are shown in Table 1 . In both the pilot and confirmatory studies, there were no differences in patient age, sex, presence of atrophic gastritis, intestinal metaplasia, or Helicobacter pylori infection. In the pilot study, the numbers of gastric cancer cases with undifferentiated histology were nine (60.0%) and eight (53.3%) in the WLE and pCLE groups, respectively (P > 0.999).
Proportion of cancer cells in biopsy samples of the pilot study. An example of histological assessment for cancer proportion in biopsy samples is shown in Figure 2 . In this figure, the five biopsy samples on the left were obtained under WLE, and the cancer proportion was 20%. In cases of biopsy samples obtained under pCLE, the cancer proportion was 60%.
In addition, the proportion of cancer cells in biopsy samples of the pilot study is shown in Figure 3 . In all lesions, the median proportion of cancer cells in the pCLE group was 60% (IQR, 40-70%), whereas that in the WLE group was 40% (IQR, 20-60%) (P = 0.136). In a subgroup analysis of cancers with undifferentiated histology, the proportion of cancer cells was significantly higher in the pCLE group than in the WLE group (WLE vs pCLE; median proportion Tissue tumor markers. In the pilot study, we compared the expression of tumor markers between cancer tissues and adjacent normal tissues. In this analysis, 11 lesions (four differentiated and seven undifferentiated cancers) in the WLE group and 11 lesions (five differentiated and six undifferentiated cancers) in the pCLE group were included because some samples showed inappropriate quality for RNA analysis. As shown in Figure S1 , tumor markers including CEA, GW112, HOTAIR, and H19 were more highly expressed in cancer tissues than in adjacent normal tissues, irrespective of differentiation and type of tumor markers. Moreover, the cancer to normal tissue ratio of tumor marker expression was compared between the WLE and pCLE groups, as shown in Figure 4 . Although statistical power was not achieved, the tumor marker expression ratio tended to be higher in the pCLE group than in the WLE group (WLE vs pCLE; CEA, 2.1 vs 3.5, P = 0.478; GW112, 7.4 vs 31.1, P = 0.151; HOTAIR, 2.0 vs 2.1, P = 0.562; H19, 15.1 vs 26.8, P = 0.519).
Proportion of cancer cells in biopsy samples of the confirmatory study. In the confirmatory study, the mean proportion of cancer cells in biopsy samples was 29.3% in the WLE group and 49.5% in the pCLE group (P = 0.002, Fig. 5a ). In addition, the number of pieces that contained cancer cells in six biopsy samples was higher in the pCLE group than in the WLE group (WLE vs pCLE: mean ± SD, 4.1 ± 1.3 vs 5.1 ± 1.1, P = 0.003). When all of the APD or SRC samples of the pilot and confirmatory studies were analyzed together, the mean proportion of cancer cells was also higher in the pCLE group than in the WLE group (WLE vs pCLE: mean ± SD, 30.2 ± 14.1 vs 52.1 ± 27.9, P < 0.001; Fig. 5b) .
Although pCLE-targeted biopsy was superior to WLE-targeted biopsy, it was impossible in two patients because no cancer cell was detected under pCLE. Both of these patients had a small SRC, revealed as being 4 and 8 mm, respectively, in histopathological examinations (Fig. S2) . In these patients, random biopsy was performed instead of pCLE-targeted biopsy. As a result, 7% and 6% of cells were shown as cancers in biopsy samples. Figure S3 shows the correlation between cancer size and proportion of cancer cells in biopsy samples. Although there was no statistical significance, the proportion of cancer cells in pCLEtargeted biopsy samples tended to increase as the cancer size increased.
Procedure time and adverse event. The procedure time was significantly longer in the pCLE group than in the WLE group in both the pilot and confirmatory studies. In the pilot study, the median procedure time was 9.5 min (IQR, 7.5-10.6 min) in the WLE group and 17.8 min (IQR, 13.6-21.7 min) in the pCLE group (P < 0.001). In the confirmatory study, the mean procedure time was 6.3 min (SD, 1.7 min) in the WLE group and 11.5 min (SD, 4.2 min) in the pCLE group (P < 0.001). Because biopsies for tumor marker assessment were not performed in the confirmatory study, the procedure time was shorter in the confirmatory study than in the pilot study. APD, poorly differentiated adenocarcinoma; NA, not available; pCLE, probe based confocal laser endomicroscopy; SD, standard deviation; SRC, signet ring cell carcinoma; WLE, white light endoscopy.
In addition, bleeding, perforation, and any other adverse event did not occur in both the WLE and pCLE groups.
Discussion
Endoscopic imaging techniques continue to develop over time. 19 Currently, the era of microscopic endoscopy including CLE is emerging. CLE has a rather high magnification and resolution, allowing digital images of cells magnified 1000-fold to be presented in real time on a monitor. 19 In the current study, we desired to expand the application field of CLE based on its high accuracy in the diagnosis of gastric cancer. If practitioners can make a diagnosis of gastric cancer in real time before biopsy and selectively collect tissues containing cancer, it will be possible to obtain fresh cancer tissues with high purity. For successful molecular genetic research and clinical applications, adequate tissue sampling is mandatory. In our study, the proportion of undifferentiated-type gastric cancer cells in biopsy samples was 29% under WLE. We consider this percentage insufficient to provide reliable results in molecular genetic research. In contrast, the proportion of cancer cells in biopsy samples obtained under pCLE examination was increased to 50. This result implies that conventional WLE is limited for cancer tissue targeting in gastric cancer with undifferentiated histology.
Generally, it is difficult to delineate gastric cancers with undifferentiated histology by using WLE. If molecular genetic approaches with endoscopic biopsy samples are planned for undifferentiated gastric cancer including APD and SRC, we strongly recommend the use of pCLE before biopsy for adequate tissue pCLE-targeted biopsysampling. In cases of differentiated cancers, however, the proportion of cancer cells did not differ between the WLE and pCLE groups. The reason for the results is that WLE is effective in the detection of differentiated-type gastric cancers and biopsy targeting. pCLE does not seem to have an advantage of exceeding WLE for gastric cancers with differentiated histology.
Although we demonstrated that the proportion of cancer cells in biopsy of undifferentiated-type gastric cancers was higher in the pCLE group than in the WLE group, it did not indicate that the diagnostic yield of pCLE was superior to WLE. In addition, the pCLE-based target biopsy requires higher cost, more effort by endoscopists, and a relatively long procedure time compared with the WLE-based biopsy. Therefore, through our study, we cannot say that pCLE is more useful for clinical purposes rather than research purposes.
Although the comparison of the proportion of cancer cells in biopsy samples between the two endoscopic modalities was the primary endpoint of the present study, we additionally compared the tumor marker expression in biopsy samples to validate our idea. CEA and GW112 are representative genes that can produce proteins. HOTAIR and H19 are long noncoding RNAs that have recently received attention because of their roles in gastric carcinogenesis. As expected, the tumor markers used in our study usually tended to show increases in biopsy samples obtained under pCLE compared with those obtained under WLE. Although statistical power was not achieved owing to the small sample size, this analysis provided a glimpse of the usefulness of pCLEtargeted biopsy for adequate tissue sampling for molecular assays including genes and RNAs.
Although we demonstrated that the proportion of cancer cells in biopsy samples was higher in the pCLE-targeted biopsy than in the WLE-targeted biopsy, the failed examination in two patients with small early gastric cancer, which had a very small amount of cancer, may demonstrate a limitation of pCLE-targeted biopsy. Theoretically, pCLE magnifies objects up to 1000 times; however, there is no way to take a very small lesion selectively because the size of biopsy forceps is 6 mm. In our study, the proportion of cancer cells in biopsy samples tended to be correlated with cancer size. pCLEtargeted biopsy may be more useful in large lesions than in small lesions.
Although this is the first study to evaluate the benefits of pCLE for molecular genetic pathology, it has several limitations. The first limitation is the fact that different biopsy samples were used for histopathological examination and assessment of tumor markers, although biopsy samples for both evaluations were acquired under the same conditions. This discrepancy may explain the somewhat conflicting results in the differentiated cancer subgroup between histopathological examination and tumor marker assessment. In cases of differentiated cancers, the proportion of cancer cells in biopsy samples tended to be higher in the WLE group than in the pCLE group; however, tumor markers tended to be higher in the pCLE group than in the WLE group. The second limitation is generalizability. pCLE is still costly and has not yet received wide acceptance in many countries. Another factor that may hinder the generalization of our results is the possible learning curve for pCLE examination. Additional subsequent studies will be required to validate our results.
Despite these limitations, we believe that our data form a basis for expanding the application field of pCLE. pCLE-targeted biopsies provided superior results in terms of the proportion of cancer cells in biopsy samples compared with WLE-targeted biopsies alone in gastric cancers with undifferentiated histology. Tumor markers including CEA, GW112, HOTAIR, and H19 tended to be more highly expressed in biopsy samples obtained under pCLE than WLE. Recently, gastric cancer tissue samples have been widely used for precision medicine, which included patient-driven xenografts and cancer organoids. 20, 21 pCLE-targeted biopsy is likely to improve the efficiency of these methods. If molecular genetic research with endoscopic biopsy samples is planned for gastric cancer cases, particularly undifferentiated gastric cancer including APD and SRC, we recommend the use of pCLE before biopsy for adequate tissue sampling. GW112, (3) HOTAIR, and (4) H19. Twenty-two lesions were included in this analysis because some samples obtained from eight lesions showed inappropriate quality for RNA analysis. Figure S3 . Correlation between cancer size and proportion of cancer cells in biopsy samples. Orange and cyan lines represent the regression line of the WLE and pCLE groups, respectively. Gray zones represent the 95% confidence intervals of the regression line. WLE, white light endoscopy; pCLE, probe-based confocal laser endomicroscopy.
